CME

Faculty: Anjali Owens, MD

Faculty: Ahmad Masri, MD, MS

This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.

Faculty: Christyn Edmundson, MD

Faculty: Gil I. Wolfe MD, FAAN

This program examines treat-to-target (T2T) principles in generalized myasthenia gravis (gMG), emphasizing measurable goals such as minimal manifestation status (MMS) and minimal symptom expression (MSE). Faculty review validated tools—including MG-ADL, QMG, and MG-QoL15r—to assess disease activity, identify uncontrolled disease, and guide escalation using the ≥2-point MG-ADL threshold. Key data from FcRn inhibitor trials, including ADAPT, MycarinG, and VIVACITY-MG3, are discussed alongside practical considerations on patient selection, IgG kinetics-based redosing, and patient-centered, interdisciplinary care.